In this week's Homerun Slides, therapeutic approaches to chronic kidney disease beyond the renin–angiotensin system.

Diet and lifestyle modification: Appropriate lifestyle interventions involving diet and exercise can lead to weight loss, and since obesity is a major contributor to the IR and T2DM, weight loss should provide significant benefits to individuals with these problems. The Diabetes Prevention Program demonstrated that a 6% weight loss and the addition of two hours of exercise per week was associated with a 58% reduction in the incidence of new T2DM in a group with IGT. Similar results were obtained in the Finnish Diabetes Prevention Study using similar interventions.

This week there was a lot of press about Abbott getting approval for their CGMS, the Libre Flash System (see item #5). The best part about this approval is the hope that there will be be more competition among the manufacturers, lower prices and increased third party coverage. This would be good based on the information we have …

Intensive control of blood pressure, glucose, and lipids benefits patients with type 2 diabetes, the long-awaited, large Japan Diabetes Optimal Integrated Treatment Study for 3 Major Risk Factors of Cardiovascular Diseases (J-DOIT3).

The results of the REMOVAL study were presented at the 2017 European Association for the Study of Diabetes (EASD) in Lisbon

Children and teenagers with type 1 diabetes are more likely to have eating disorders.

The investigational sodium/glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin (Merck), being developed to improve glycemic control in adults with type 2 diabetes, met the primary outcomes in two yearlong phase 3 trials, VERTIS SU and VERTIS SITA2.

First Continuous Glucose Monitor that doesn’t require routine finger pricks.

One of your patients is a 3-state regional salesman who has a fairly unpredictable work schedule. When he gets hungry while on the road, he tends to eat at the first restaurant he sees. For the past 3 months, he has managed his type 2 diabetes with metformin, glipizide, and glargine. Despite this regimen, his current A1C is 7.8%. You are in agreement that he needs to add a bolus insulin dose to his regimen. Which type of insulin would be the most appropriate choice? 1. Rapid-acting insulin analogues 2. Premixed insulin 3. Long-acting insulin analogues 4. Intermediate-acting insulin Follow the link to see the correct answer.

Which new drug do you prefer for a second-line therapy for a patient with type 2 patient diabetes? 1) GLP-1 Agonist 2) SGLT-2 Inhibitor 3) Long-acting insulin 4) TZD 5) Other Follow the link to share your response.